Total trials
1,321
Active
217
Phase 3
77
Total enrollment
1,909,133
Pipeline matrix
Showing 40 of 48 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Budesonide Nasal | — | — | — | — | — | 1 | |
| Pharmacological Rate Control | — | — | — | — | — | 1 | |
| Budesonide | — | — | — | — | — | 1 | |
| Tranexamic Acid | — | — | — | — | — | 1 | |
| Tacrolimus, Immediate Release, | — | — | — | — | — | 1 | |
| Tacrolimus Extended Release Oral | — | — | — | — | — | 1 | |
| Nerandomilast 18 mg - adult formulation | — | — | — | — | — | 1 | |
| RSVpreF | — | — | — | — | — | 1 | |
| LABA+LAMA | — | — | — | — | — | 1 | |
| LABA+LAMA+ICS | — | — | — | — | — | 1 | |
| Nonavalent HPV vaccine | — | — | — | — | — | 1 | |
| methadone | — | — | — | — | — | 3 | |
| Buprenorphine/naloxone | — | — | — | — | 2 | ||
| Ustekinumab | — | — | — | — | 2 | ||
| ST-02 | — | — | — | — | — | 1 | |
| Cannabidiol | — | — | — | — | — | 1 | |
| duloxetine | — | — | — | — | — | 1 | |
| ST-01 | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Lemborexant 5 mg | — | — | — | — | — | 1 | |
| Control (placebo) group | — | — | — | — | — | 1 | |
| Indomethacin | — | — | — | — | — | 1 | |
| Apo-levocarb | — | — | — | — | — | 1 | |
| Psilocybin-assisted Psychotherapy | — | — | — | — | — | 1 | |
| Apalutamide 60mg Tab | — | — | — | — | — | 1 | |
| Abiraterone Acetate 250mg | — | — | — | — | — | 1 | |
| Prednisone 5mg Tab | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Niraparib 100mg Oral | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Cannabis oil with a high ratio of THC to CBD | — | — | — | — | — | 1 | |
| Cannabis oil with a high ratio of CBD to THC | — | — | — | — | — | 1 | |
| Salbutamol | — | — | — | — | 4 | ||
| Trikafta | — | — | — | — | — | 2 | |
| Prednisone | — | — | — | — | 3 | ||
| GnRH antagonist | — | — | — | — | — | 1 | |
| Estradiol | — | — | — | — | — | 1 | |
| Testosterone | — | — | — | — | — | 1 | |
| Anastrozole | — | — | — | — | — | 1 | |
| MI-Coach: ED Mobile App | — | — | — | — | — | 1 |
8 more active programs hidden
Next readouts
- 2025-12-31
- 2025-12-31
- 2026-01-01
- 2026-02-01
- 2026-03
- 2026-03
- 2026-04
- 2026-04-01
- 2026-04-27
- 2026-04-27
Top conditions
- Stroke23
- Spinal Cord Injuries22
- Healthy21
- Pregnancy19
- Type 2 Diabetes19
- Pain18
- Cystic Fibrosis16
- Depression15
Frequently asked questions about University of British Columbia
- How many clinical trials does University of British Columbia have on ClinicalTrials.gov?
- University of British Columbia is listed as the lead sponsor on 1,321 clinical trials in ClinicalTrials.gov, 217 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of British Columbia's trials are in Phase 3?
- 77 of University of British Columbia's trials are in Phase 3, spread across 48 active drug programs.
- What therapeutic areas does University of British Columbia focus on?
- University of British Columbia's most-studied conditions on ClinicalTrials.gov are Stroke, Spinal Cord Injuries, Healthy, Pregnancy, Type 2 Diabetes.
- When are University of British Columbia's next clinical trial readouts?
- University of British Columbia has 10 upcoming primary-completion readouts tracked here; the soonest is “Epigenetic Health Benefits of Budesonide”, expected around 2025-12-31.